# Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults

> **NCT01440569** · PHASE3 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 314 (actual)

## Conditions studied

- Acquired Immunodeficiency Syndrome
- HIV Infections

## Interventions

- **DRUG:** COBI
- **DRUG:** DRV
- **DRUG:** NRTIs

## Key facts

- **NCT ID:** NCT01440569
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2012-08
- **Final completion:** 2015-10
- **Target enrollment:** 314 (ACTUAL)
- **Last updated:** 2016-12-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01440569

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01440569, "Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01440569. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*